Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide (OVA-LGG)

Inclusion Criteria:

• Premenopausal women ages 18-44 newly diagnosed with LGG
• Patients fulfill the inclusion criteria for UCSF Protocol Number: CC #99102 " A Phase II Study of Temozolomide (TEMODAR) in the Treatment of Adult Patients with Supratentorial Low Grade Glioma"
• Patients with histologically proven supratentorial low grade glioma.
• Patients may or may not have had a surgical resection.
• Patients must be expected to live the length of study
• Patients must be able to provide informed consent according to institutional guidelines.

Exclusion Criteria:

• Prior ovarian resection, unilateral or bilateral oophorectomy, hysterectomy or radiation to pelvic region.
• Pregnancy or breast feeding.
• Diagnosis of another malignancy, unless the patient was diagnosed at least 2 years earlier and has been disease-free for at least 6 months following the completion of curative intent therapy with the following exceptions: Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed.
• Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
• Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
• Patient is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs, substance abuse or had a recent history (within the last year) of drug or alcohol abuse
• Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study or is not in the best interest of the patient.